Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$75,687.00+0.29%ETH$2,393.22-0.03%GOLD$4,297.20-2.06%OIL$101.95-0.47%
Smart Investors Daily
SR

NASDAQ · SRZN

Surrozen, Inc.

Healthcare · Biotechnology

$17.77

Down-$0.84 (-4.73%)

Updated Sep 16, 2026, 9:56 PM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
201.6M
P/E ratio
-12.03
Dividend yield
0.00%
52-week range
$11.25 – $35.00
Volume
151.94K
Avg. volume
63.79K

Price performance

SRZN price history

1M range · 20 trading sessions · Daily adjusted prices

SRZN closed at $17.77 after 20 trading sessions, down 25.96% for the selected period.

Last close
$17.77
Period change
-25.96%
Period low
$17.77
Period high
$24.01
Daily close
View OHLC price history
SRZN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$17.81$18.34$17.15$17.77151.94K
Sep 14, 2026$19.03$19.29$17.61$17.84198.2K
Sep 11, 2026$19.68$19.72$18.71$19.00145.34K
Sep 10, 2026$19.95$20.15$18.995$19.45277.75K
Sep 9, 2026$20.52$20.52$18.40$20.03206.97K
Sep 8, 2026$22.57$23.18$20.63$20.68202.33K
Sep 4, 2026$22.34$22.90$21.535$22.76150.24K
Sep 3, 2026$22.92$22.99$22.24$22.54200.87K
Sep 2, 2026$22.32$23.005$21.895$22.60116.91K
Sep 1, 2026$21.72$22.475$21.651$22.20124.63K
Aug 31, 2026$22.28$22.62$21.45$22.02266.75K
Aug 28, 2026$23.75$23.75$22.08$22.42239.36K
Aug 27, 2026$23.69$24.87$23.03$24.01340.75K
Aug 26, 2026$23.52$24.16$23.19$23.71128.75K
Aug 25, 2026$23.97$25.01$23.29$23.36218.97K
Aug 24, 2026$23.81$24.33$22.80$23.97163.64K
Aug 21, 2026$23.73$25.01$23.49$23.99149.72K
Aug 20, 2026$24.46$24.46$23.085$23.50135.33K
Aug 19, 2026$24.44$24.50$23.77$24.01122.46K
Aug 18, 2026$23.50$24.69$23.43$24.00148.58K

Latest SRZN news

The latest Smart Investors Daily articles mentioning SRZN.

Stock researchCompany · Overview

SRZN research

Overview

Company profile and research snapshot.

Company profile

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$38.50
Implied upside
—
Analysts
8
SRZN recent ratings
DateFirmRatingTarget
Aug 20, 2026William BlairOutperform—
Aug 10, 2026HC Wainwright & Co.Buy—
May 7, 2026HC Wainwright & Co.Buy—
Apr 21, 2026TD CowenBuy—
Mar 24, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endo

Yahoo · Sep 2, 2026

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences. 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 Fireside Chat at

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By